Thursday, March 28, 2024

Creating liberating content

Oracle Corp’s (NYSE: ORCL)...

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15%...

RTX Corp (NYSE: RTX)...

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03...

GameStop Corp. (NYSE:GME) Quarter...

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after...

Advanced Micro Devices (NASDAQ:AMD)...

Shares of Advanced Micro Devices (NASDAQ:AMD) drops 0.38% in afterhours in last trading...
HomeBiotech-PharmaSoleno Therapeutics, Inc....

Soleno Therapeutics, Inc. (NASDAQ: SLNO) Signs A Securities Purchase Agreement Up to $60 Million

Soleno Therapeutics, Inc. (NASDAQ: SLNO) reported that it has signed a securities purchase agreement for up to $60 million with Nantahala Capital Management, LLC, Abingworth LLP, and Vivo Capital, LLC.

Chief Executive Officer of Soleno Therapeutics, Anish Bhatnagar stated that prior to anticipated findings from the randomized withdrawal period of Study C602 in mid-2023, this pledge from top-tier investors is a major expression of trust. It improves their financial sheet both now and in the future, supports ongoing work on their upcoming New Drug Application application, and speeds up commercial ready preparations. Additionally, they are happy to inform that the rate of study enrollment at their U.S. sites is proceeding according to plan. The timeliness of regional regulatory and ethical processes will determine when they launch their U.K. sites.

Under the terms of the agreement, the investors have committed to pay $10 million in exchange for warrants to purchase common stock upon the Company’s announcement of enrollment completion in the randomized withdrawal period of Study C602, anticipated in Q1 2023. The warrants consist of two tranches.

Within 30 days after the release of good top-line data from the randomized withdrawal period of Study C602, Tranche A warrants to acquire up to 8,598,870 shares of common stock at $1.75 for a total of roughly $15 million must be exercised. The $35 million Tranche B warrants to acquire up to 14,000,000 shares of common stock at $2.50 expire 3.5 years after the date of issuance or 30 days after receiving U.S. Food and Drug Administration clearance of DCCR for the treatment of PWS, whichever comes first.

Approximately 80 patients with PWS were included in the randomized withdrawal phase of Investigation C602, a multi-center, randomized, double-blind, placebo-controlled study of DCCR at 17 locations in the United States and 5 sites in the United Kingdom. Participants who are presently participating in Study C602 are the only patients who can withdraw randomly from the study. For a four-month period, patients are randomized to receive either DCCR or a placebo.

 

Oracle Corp’s (NYSE: ORCL) Cloud Business Faces Headwinds: What Lies Ahead

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15% or $15.21 to trade at $111.50 in pre trading session on...

RTX Corp (NYSE: RTX) Updates 2023-2025 Outlook amid Engine Part Challenge

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03 per share, bringing its current trading price to $77.45. The company,...

GameStop Corp. (NYSE:GME) Quarter Report: Resilience amidst Market Turbulence

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after the market closes today. Shares were slightly down in the pre-trading...

Continue reading

Alphabet Inc. (NASDAQ: GOOGL) In Talks to Reduce European IT Jobs After ‘Disastrous’ Layoffs

Shares of Alphabet Inc. (NASDAQ: GOOGL) inches down in pre session on Thursday after big American IT businesses are suddenly discovering how hard it is to decrease personnel in Europe after announcing the greatest rounds of layoffs in their...

Apple Inc. (NASDAQ: AAPL) Unveils Appearance of Its First Retail Location in India

Shares of Apple Inc. (NASDAQ: AAPL) inches down in afterhours trading as many people rushed to get a glance of the store's black and yellow artwork, which was modeled after Mumbai's famous cabs, as the company unveiled the appearance...

Credit Suisse (NYSE: CS) and UBS Group AG (NYSE: UBS) In Flux after Probe into Credit Suisse Acquisition

Credit Suisse (NYSE: CS) and UBS Group AG (NYSE: UBS) shares revamp its position on Tuesday from previous session following the emergency merger of the two lenders was the subject of an inquiry by Switzerland's federal prosecutor. The prosecutor has...

Enjoy exclusive access to all of our content

Get an online subscription and you can unlock any article you come across.